GENO Genovis AB (publ.)

2.303USD23.40 SEK · STO+4.00%Mkt Cap: 155.37M USDP/E: 93.60

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOU…

Institutional holders2 on file

Key Statistics

Company
Market Cap155.37M USD
Enterprise Value146.26M USD
Revenue (TTM)14.29M USD
Gross Profit11.40M USD
Net Income (TTM)2.31M USD
Revenue/Share0.21 USD
Last Price2.303 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees43
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002485979
Valuation
P/E (Trailing)93.60
P/E (Forward)49.79
PEG—
EV/EBITDA44.86
EV/Revenue10.23
P/S10.87
P/B5.03
EPS (TTM)0.02 USD
EPS (Forward)0.05 USD
52W Range
1.53987% of range2.416
52W High2.416 USD
52W Low1.539 USD
Profitability
Gross Margin89.85%
Oper. Margin16.61%
EBITDA Margin22.81%
Profit Margin18.22%
ROE8.65%
ROA6.22%
ROIC13.44%
ROCE7.95%
Growth
Revenue Growth33.90%
Earnings Growth-49.20%
Cash Flow & Leverage
Operating CF3.15M USD
CapEx (TTM)1.23M USD
FCF Margin16.37%
FCF Yield1.51%
Net Debt-9.11M USD
Net Debt/EBITDA-2.80
Net Debt/FCF-3.90
Balance Sheet
Debt/Equity0.27
Current Ratio4.76
Quick Ratio3.61
Book Value/Sh0.46 USD
Cash/Share0.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 4, 2012
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.347 USD
Upside (mean)+45.3%
Target Range2.953 USD – 3.740 USD
2.953+45.3% to mean3.740
# Analysts2
Ownership
Shares Out.67.46M
Float56.52M
Insiders16.79%
Institutions36.93%
Technical
SMA 502.035 (+13.2%)
SMA 2001.924 (+19.7%)
Beta1.71
S&P 52W Chg12.00%
Avg Vol (30d)194.75K
Avg Vol (10d)277.37K
Technical Indicators
RSI (14)63.4
MACD0.7380
MACD Signal0.6898
MACD Hist.+0.0482
BB Upper2.401 USD
BB Middle2.181 USD
BB Lower1.962 USD
BB Width20.14%
ATR (14)0.1044 USD
Vol Ratio (20d)0.89x

About Genovis (STO: GENO)

›

Genovis (STO: GENO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 43 employees.

The shares were at 23.40 SEK on 19 November 2026, up 14.1% over 52 weeks. Its 52-week range is 15.64 SEK to 24.55 SEK: the price is 4.7% below the high and 49.6% above the low.

At a market capitalisation of 1.58B SEK, it trades at 93.6 times trailing earnings and 49.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 179% for GENO.

Genovis reports return on equity of 8.7%, an operating margin of 16.6% and revenue up 33.9% year over year.

It holds more cash than debt, a net cash position of 92.59M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 34.00 SEK is 45.3% above the current price.